Dr. Lal PathLabs Limited has announced several key decisions following its board meeting on April 30, 2026. The company has approved the audited financial results for the quarter and financial year ending March 31, 2026, and has recommended a final dividend of ₹4 per equity share, representing a 40% payout on a face value of ₹10 per share. This dividend is subject to approval at the upcoming Annual General Meeting (AGM), and the record date for the dividend is set for June 26, 2026.
In addition to the financial results, Dr. Lal PathLabs has also announced the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL). This acquisition will result in SDCPL becoming a wholly-owned subsidiary of Dr. Lal PathLabs, marking a significant expansion in the company’s operations.
The board also approved the incorporation of a wholly-owned subsidiary in Dubai, United Arab Emirates, named Dr. Lal PathLabs FZCO, pending necessary regulatory approvals. This move is part of the company’s strategy to expand its international footprint.
Furthermore, the board has re-appointed (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director for a five-year term starting April 1, 2027, and Mr. Rajit Mehta as a Non-Executive Independent Director for a five-year term commencing July 27, 2026. Both appointments are subject to approval at the AGM.
In terms of senior management, Dr. Reena Nakra has been designated as the Chief Scientific Officer, and Dr. Saloni Khera as the Chief Lab Management Officer, both effective from April 30, 2026.
The company has also re-appointed M/s Ernst & Young LLP as Internal Auditors and M/s A.G. Agarwal & Associates as Cost Auditors for the financial year 2026-27. Additionally, 82,750 equity shares were allotted under the Employee Stock Option Plan 2022, increasing the paid-up equity share capital to ₹1,67,63,77,700.
Finally, Dr. Lal PathLabs has scheduled its 32nd Annual General Meeting for July 25, 2026, to be held via video conferencing.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).